Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Austin, TX
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Corpus Christi, TX
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Galveston, TX
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Galveston, TX
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Houston, TX
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Richardson, TX
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Richardson, TX
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
San Antonio, TX
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Salt Lake City, UT
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Norfolk, VA
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Richmond, VA
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Spokane, WA
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Tacoma, WA
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Yakima, WA
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Yakima, WA
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Charleston, WV
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Charleston, WV
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
La Crosse, WI
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
La Crosse, WI
Click here to add this to my saved trials
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated:  9/1/2015
GSK Investigational Site
mi
from
Broadmeadow,
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain
Status: Enrolling
Updated: 9/1/2015
GSK Investigational Site
mi
from
Broadmeadow,
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
Jupiter, FL
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
Jupiter, FL
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
South Miami, FL
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
Towson, MD
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
Towson, MD
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
New York, NY
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
High Point, NC
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
Raleigh, NC
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
Dallas, TX
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
Houston, TX
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
San Antonio, TX
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated:  9/3/2015
Clinical Research Facility
mi
from
Cheseapeake, VA
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Status: Enrolling
Updated: 9/3/2015
Clinical Research Facility
mi
from
Cheseapeake, VA
Click here to add this to my saved trials
Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass
Losing More Than Just Weight: Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass
Status: Enrolling
Updated:  9/4/2015
Gundersen Lutheran Health System
mi
from
La Crosse, WI
Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass
Losing More Than Just Weight: Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass
Status: Enrolling
Updated: 9/4/2015
Gundersen Lutheran Health System
mi
from
La Crosse, WI
Click here to add this to my saved trials
TICAP - Titanium Clips for Appendiceal Stump Closure
Prospective Multicenter Observational Study (Registry) on the Aesculap DS Titanium Ligation Clips for Appendiceal Stump Closure.
Status: Enrolling
Updated:  9/8/2015
Marina del Rey Hospital
mi
from
Marina del Rey, CA
TICAP - Titanium Clips for Appendiceal Stump Closure
Prospective Multicenter Observational Study (Registry) on the Aesculap DS Titanium Ligation Clips for Appendiceal Stump Closure.
Status: Enrolling
Updated: 9/8/2015
Marina del Rey Hospital
mi
from
Marina del Rey, CA
Click here to add this to my saved trials
TICAP - Titanium Clips for Appendiceal Stump Closure
Prospective Multicenter Observational Study (Registry) on the Aesculap DS Titanium Ligation Clips for Appendiceal Stump Closure.
Status: Enrolling
Updated:  9/8/2015
St. Luke's University Hospital
mi
from
Bethlehem, PA
TICAP - Titanium Clips for Appendiceal Stump Closure
Prospective Multicenter Observational Study (Registry) on the Aesculap DS Titanium Ligation Clips for Appendiceal Stump Closure.
Status: Enrolling
Updated: 9/8/2015
St. Luke's University Hospital
mi
from
Bethlehem, PA
Click here to add this to my saved trials
TICAP - Titanium Clips for Appendiceal Stump Closure
Prospective Multicenter Observational Study (Registry) on the Aesculap DS Titanium Ligation Clips for Appendiceal Stump Closure.
Status: Enrolling
Updated:  9/8/2015
Vivantes Humboldt-Klinikum
mi
from
Berlin,
TICAP - Titanium Clips for Appendiceal Stump Closure
Prospective Multicenter Observational Study (Registry) on the Aesculap DS Titanium Ligation Clips for Appendiceal Stump Closure.
Status: Enrolling
Updated: 9/8/2015
Vivantes Humboldt-Klinikum
mi
from
Berlin,
Click here to add this to my saved trials
AbsorbaTack Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair
Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair: A Prospective, Randomized Comparison to Evaluate the Incidence of Post-operative Pain Associated With Absorbable Fixation (AbsorbaTack) vs Conventional Fixation (ProTack) Following Laparoscopic Hernia Repair
Status: Enrolling
Updated:  9/9/2015
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
AbsorbaTack Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair
Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair: A Prospective, Randomized Comparison to Evaluate the Incidence of Post-operative Pain Associated With Absorbable Fixation (AbsorbaTack) vs Conventional Fixation (ProTack) Following Laparoscopic Hernia Repair
Status: Enrolling
Updated: 9/9/2015
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
AbsorbaTack Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair
Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair: A Prospective, Randomized Comparison to Evaluate the Incidence of Post-operative Pain Associated With Absorbable Fixation (AbsorbaTack) vs Conventional Fixation (ProTack) Following Laparoscopic Hernia Repair
Status: Enrolling
Updated:  9/9/2015
Greenville Hospital System
mi
from
Greenville, SC
AbsorbaTack Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair
Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair: A Prospective, Randomized Comparison to Evaluate the Incidence of Post-operative Pain Associated With Absorbable Fixation (AbsorbaTack) vs Conventional Fixation (ProTack) Following Laparoscopic Hernia Repair
Status: Enrolling
Updated: 9/9/2015
Greenville Hospital System
mi
from
Greenville, SC
Click here to add this to my saved trials
Distress Tolerance and Buprenorphine
Distress Tolerance and Reducing Early Relapse in Buprenorphine Patients
Status: Enrolling
Updated:  9/9/2015
Butler Hospital
mi
from
Providence, RI
Distress Tolerance and Buprenorphine
Distress Tolerance and Reducing Early Relapse in Buprenorphine Patients
Status: Enrolling
Updated: 9/9/2015
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects
Status: Enrolling
Updated:  9/9/2015
Advanced Clinical Research Institute
mi
from
Anaheim, CA
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects
Status: Enrolling
Updated: 9/9/2015
Advanced Clinical Research Institute
mi
from
Anaheim, CA
Click here to add this to my saved trials
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects
Status: Enrolling
Updated:  9/9/2015
Orlando Clinical Research Center
mi
from
Orlando, FL
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects
Status: Enrolling
Updated: 9/9/2015
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy.
Status: Enrolling
Updated:  9/15/2015
Ohio State University
mi
from
Columbus, OH
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy.
Status: Enrolling
Updated: 9/15/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts
3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts
Status: Enrolling
Updated:  9/15/2015
University of Michigan Hospital
mi
from
Ann Arbor, MI
3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts
3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts
Status: Enrolling
Updated: 9/15/2015
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease
A Prospective Trial of Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease
Status: Enrolling
Updated:  9/16/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease
A Prospective Trial of Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease
Status: Enrolling
Updated: 9/16/2015
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease
hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease
Status: Enrolling
Updated:  9/21/2015
Massachusetts Institute of Technology
mi
from
Cambridge, MA
hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease
hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease
Status: Enrolling
Updated: 9/21/2015
Massachusetts Institute of Technology
mi
from
Cambridge, MA
Click here to add this to my saved trials
Bowel Function After Minimally Invasive Urogynecologic Surgery
Bowel Function After Minimally Invasive Urogynecologic Surgery: A Prospective Randomized Controlled Trial
Status: Enrolling
Updated:  9/21/2015
University of Rochester
mi
from
Rochester, NY
Bowel Function After Minimally Invasive Urogynecologic Surgery
Bowel Function After Minimally Invasive Urogynecologic Surgery: A Prospective Randomized Controlled Trial
Status: Enrolling
Updated: 9/21/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
Status: Enrolling
Updated:  9/21/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
Status: Enrolling
Updated: 9/21/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Racial Disparity in Barrett's Esophagus
Racial Disparity in Barrett's Esophagus
Status: Enrolling
Updated:  9/21/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Racial Disparity in Barrett's Esophagus
Racial Disparity in Barrett's Esophagus
Status: Enrolling
Updated: 9/21/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Immune Ablation and Stem Cell Support for Crohn's Disease
Immune Ablation and Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease
Status: Enrolling
Updated:  9/21/2015
Children's Memorial Hospital
mi
from
Chicago, IL
Immune Ablation and Stem Cell Support for Crohn's Disease
Immune Ablation and Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease
Status: Enrolling
Updated: 9/21/2015
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy
Near Infrared Fluorescence Cholangiography During Cholecystectomy
Status: Enrolling
Updated:  9/22/2015
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy
Near Infrared Fluorescence Cholangiography During Cholecystectomy
Status: Enrolling
Updated: 9/22/2015
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Mesa, AZ
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Carlsbad, CA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Castro Valley, CA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Fresno, CA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Fresno, CA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Laguna Hills, CA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Laguna Hills, CA
Click here to add this to my saved trials